Real world outcomes in patients with newly diagnosed multiple myeloma treated with triplet regimens lenalidomide, bortezomib and dexamethasone and cyclophosphamide, bortezomib and dexamethasone: a retrospective, observational study

Trial Profile

Real world outcomes in patients with newly diagnosed multiple myeloma treated with triplet regimens lenalidomide, bortezomib and dexamethasone and cyclophosphamide, bortezomib and dexamethasone: a retrospective, observational study

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Dec 2017

At a glance

  • Drugs Bortezomib (Primary) ; Cyclophosphamide (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Dec 2017 New trial record
    • 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top